The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

"Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Rezdiffra is used in adults to treat nonalcoholic steatohepatitis (NASH) in certain situations, along with diet and exercise. NASH involves a buildup of fat in your liver that can cause ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Meena Bansal, MD, and Naga Chalasani, MD, discuss how FibroScan, lab data, and careful noninvasive assessments help hepatologists identify the right candidates for Rezdiffra—without needing ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients.

Following the latest nod, Rezdiffra became the first and only therapy to be approved for the treatment of MASH in the European Union (EU). The approval was based on Rezdiffra’s favorable benefit-risk ...